Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA.

Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15.

2.

Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients.

Bonomi P, Fidler MJ, Shah P, Borgia J.

Cancers (Basel). 2019 Oct 23;11(11). pii: E1619. doi: 10.3390/cancers11111619.

3.

Prognostic Significance of Skeletal Muscle Loss During Early Postoperative Period in Elderly Patients with Esophageal Cancer.

Fidler MJ, Borgia JA, Bonomi PD, Shah P.

Ann Surg Oncol. 2019 Nov;26(12):3807-3808. doi: 10.1245/s10434-019-07721-0. Epub 2019 Aug 30. No abstract available.

PMID:
31471841
4.

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV.

J Clin Oncol. 2019 Feb 1;37(4):278-285. doi: 10.1200/JCO.18.01585. Epub 2018 Dec 14.

5.

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.

Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JC, Garrido P, Rittmeyer A, Tiseo M, Meyenberg C, de Haas S, Lam LH, Lu MW, Stinchcombe TE.

Clin Cancer Res. 2019 Jan 1;25(1):64-72. doi: 10.1158/1078-0432.CCR-18-1590. Epub 2018 Sep 11.

6.

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.

Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA Jr, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N.

Ann Oncol. 2018 Aug 1;29(8):1701-1709. doi: 10.1093/annonc/mdy196. Review.

7.

Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria.

Bonomi P, Blumenthal G, Ferris AS, Stewart DJ, Selig WKD, Krug LM, Allen J, Ison G, Langer CJ, Melemed A, Odogwu L, Basu Roy U, Sandler A.

J Thorac Oncol. 2018 Jun;13(6):748-751. doi: 10.1016/j.jtho.2018.02.013. No abstract available.

8.

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).

Gadgeel SM, Pennell NA, Fidler MJ, Halmos B, Bonomi P, Stevenson J, Schneider B, Sukari A, Ventimiglia J, Chen W, Galasso C, Wozniak A, Boerner J, Kalemkerian GP.

J Thorac Oncol. 2018 Sep;13(9):1393-1399. doi: 10.1016/j.jtho.2018.05.002. Epub 2018 Jul 17.

9.

Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies.

Hirsch FR, Kerr KM, Bunn PA Jr, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N.

Clin Lung Cancer. 2018 Jul;19(4):331-339. doi: 10.1016/j.cllc.2018.03.014. Epub 2018 Mar 21. Review.

10.

The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.

Fidler MJ, Fhied CL, Roder J, Basu S, Sayidine S, Fughhi I, Pool M, Batus M, Bonomi P, Borgia JA.

BMC Cancer. 2018 Mar 20;18(1):310. doi: 10.1186/s12885-018-4193-0.

11.

Development of bead based multiplexed immunoassay for evaluation of midkine, syndecan-1, and ANGPTL4 in patient serum.

Tarhoni I, Fhied CL, Pool M, Liptay MJ, Bonomi P, Seder CW, Borgia JA.

J Immunoassay Immunochem. 2018;39(1):84-98. doi: 10.1080/15321819.2017.1407338. Epub 2018 Feb 2.

PMID:
29309212
12.

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.

Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA Jr, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Wakelee H, Thatcher N.

J Thorac Oncol. 2018 Feb;13(2):165-183. doi: 10.1016/j.jtho.2017.11.111. Epub 2017 Nov 23. Review.

13.

Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy.

Fidler MJ, Frankenberger C, Seto R, Lobato GC, Fhied CL, Sayidine S, Basu S, Pool M, Karmali R, Batus M, Lie WR, Hayes D, Mistry J, Bonomi P, Borgia JA.

Oncotarget. 2017 Apr 28;8(35):58108-58121. doi: 10.18632/oncotarget.17510. eCollection 2017 Aug 29.

14.

Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy.

Cooper DS, Meriggioli MN, Bonomi PD, Malik R.

J Neuromuscul Dis. 2017;4(2):169-173. doi: 10.3233/JND-170219.

PMID:
28505981
15.

Practical and theoretical implications of weight gain in advanced non-small cell lung cancer patients.

Bonomi P, Batus M, Fidler MJ, Borgia JA.

Ann Transl Med. 2017 Mar;5(6):152. doi: 10.21037/atm.2017.03.20. No abstract available.

16.

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).

Awad MM, Chu QS, Gandhi L, Stephenson JJ, Govindan R, Bradford DS, Bonomi PD, Ellison DM, Eaton KD, Fritsch H, Munzert G, Johnson BE, Socinski MA.

Lung Cancer. 2017 Feb;104:126-130. doi: 10.1016/j.lungcan.2016.12.019. Epub 2016 Dec 30.

PMID:
28212994
17.

Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer.

Derman BA, Macklis JN, Azeem MS, Sayidine S, Basu S, Batus M, Esmail F, Borgia JA, Bonomi P, Fidler MJ.

BMC Cancer. 2017 Feb 16;17(1):141. doi: 10.1186/s12885-017-3122-y.

18.

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment.

Langer CJ, Obasaju C, Bunn P, Bonomi P, Gandara D, Hirsch FR, Kim ES, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Socinski MA, Spigel DR, Wakelee H, Mayo C, Thatcher N.

J Thorac Oncol. 2016 Dec;11(12):2066-2081. doi: 10.1016/j.jtho.2016.08.138. Epub 2016 Aug 26. Review.

19.

Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

Waqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Jänne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM.

J Thorac Oncol. 2016 Sep;11(9):1387-96. doi: 10.1016/j.jtho.2016.05.009. Epub 2016 Jul 9. Review.

20.

Clinicopathologic Features of Advanced Squamous NSCLC.

Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Stinchcombe TE, Wakelee H, Mayo C, Thatcher N.

J Thorac Oncol. 2016 Sep;11(9):1411-22. doi: 10.1016/j.jtho.2016.05.024. Epub 2016 Jun 11. Review.

21.

A New Versatile Water-Soluble Iniferter Platform for the Preparation of Molecularly Imprinted Nanoparticles by Photopolymerisation in Aqueous Media.

Bonomi P, Attieh MD, Gonzato C, Haupt K.

Chemistry. 2016 Jul 11;22(29):10150-4. doi: 10.1002/chem.201600750. Epub 2016 Jun 8.

PMID:
27273253
22.

Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients.

Patel JD, Pereira JR, Chen J, Liu J, Guba SC, John WJ, Orlando M, Scagliotti G, Bonomi PD.

Ann Oncol. 2016 Aug;27(8):1612-9. doi: 10.1093/annonc/mdw211. Epub 2016 May 23.

23.

The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.

Reck M, Socinski MA, Luft A, Szczęsna A, Dediu M, Ramlau R, Losonczy G, Molinier O, Schumann C, Gralla RJ, Bonomi P, Brown J, Soldatenkova V, Chouaki N, Obasaju C, Peterson P, Thatcher N.

J Thorac Oncol. 2016 Jun;11(6):808-18. doi: 10.1016/j.jtho.2016.03.002. Epub 2016 Mar 12.

24.

Treatment of advanced squamous cell carcinoma of the lung: a review.

Derman BA, Mileham KF, Bonomi PD, Batus M, Fidler MJ.

Transl Lung Cancer Res. 2015 Oct;4(5):524-32. doi: 10.3978/j.issn.2218-6751.2015.06.07. Review.

25.

Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response.

Ziel E, Hermann G, Sen N, Bonomi P, Liptay MJ, Fidler MJ, Batus M, Warren WH, Chmielewski G, Sher DJ.

J Thorac Oncol. 2015 Oct;10(10):1475-80. doi: 10.1097/JTO.0000000000000639.

26.

Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale.

O'Mahony S, Nathan S, Mohajer R, Bonomi P, Batus M, Fidler MJ, Wells K, Kern N, Sims S, Amin D.

Am J Hosp Palliat Care. 2016 May;33(4):374-80. doi: 10.1177/1049909115570707. Epub 2015 Feb 10.

PMID:
25670717
27.
28.

Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung.

Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR.

Oncoscience. 2014 Aug 7;1(8):522-528. eCollection 2014.

29.

Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer.

Reynolds CH, Patel JD, Garon EB, Olsen MR, Bonomi P, Govindan R, Pennella EJ, Liu J, Guba SC, Li S, Spigel DR, Hermann RC, Socinski MA, Obasaju CK.

Clin Lung Cancer. 2015 May;16(3):200-8. doi: 10.1016/j.cllc.2014.11.004. Epub 2014 Nov 18.

PMID:
25516338
30.

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.

Doebele RC, Spigel D, Tehfe M, Thomas S, Reck M, Verma S, Eakle J, Bustin F, Goldschmidt J Jr, Cao D, Alexandris E, Yurasov S, Camidge DR, Bonomi P.

Cancer. 2015 Mar 15;121(6):883-92. doi: 10.1002/cncr.29132. Epub 2014 Nov 6.

31.

Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma.

Daly S, Kubasiak JC, Rinewalt D, Pithadia R, Basu S, Fhied C, Lobato GC, Seder CW, Hong E, Warren WH, Chmielewski G, Liptay MJ, Bonomi P, Borgia JA.

Ann Thorac Surg. 2014 Dec;98(6):1968-75; discussion 1975. doi: 10.1016/j.athoracsur.2014.06.071. Epub 2014 Oct 7.

PMID:
25301368
32.

A disposable evanescent wave fiber optic sensor coated with a molecularly imprinted polymer as a selective fluorescence probe.

Ton XA, Acha V, Bonomi P, Tse Sum Bui B, Haupt K.

Biosens Bioelectron. 2015 Feb 15;64:359-66. doi: 10.1016/j.bios.2014.09.017. Epub 2014 Sep 8.

PMID:
25259879
33.

Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.

Garg S, Gielda BT, Kiel K, Turian JV, Fidler MJ, Batus M, Bonomi P, Sher DJ.

Pract Radiat Oncol. 2014 Sep-Oct;4(5):342-348. doi: 10.1016/j.prro.2013.12.002. Epub 2014 Jan 16.

PMID:
25194104
34.

Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer.

Dandekar VK, Young J, Kiel K, Bonomi P, Fidler MJ, Batus M, Sher DJ.

Am J Clin Oncol. 2015 Dec;38(6):605-9. doi: 10.1097/COC.0000000000000007.

PMID:
24781341
35.

Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection.

Garg S, Gielda BT, Turian JV, Liptay M, Warren WH, Bonomi P, Sher DJ.

Pract Radiat Oncol. 2013 Oct-Dec;3(4):287-93. doi: 10.1016/j.prro.2012.09.002. Epub 2012 Oct 10.

PMID:
24674400
36.

Modulation of the microenvironment surrounding the active site of penicillin G acylase immobilized on acrylic carriers improves the enzymatic synthesis of cephalosporins.

Bonomi P, Bavaro T, Serra I, Tagliani A, Terreni M, Ubiali D.

Molecules. 2013 Nov 20;18(11):14349-65. doi: 10.3390/molecules181114349.

37.

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R.

J Clin Oncol. 2013 Dec 1;31(34):4349-57. doi: 10.1200/JCO.2012.47.9626. Epub 2013 Oct 21.

38.

Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials.

Dahlberg SE, Schiller JH, Bonomi PB, Sandler AB, Brahmer JR, Ramalingam SS, Johnson DH.

J Thorac Oncol. 2013 Sep;8(9):1121-7. doi: 10.1097/JTO.0b013e31829cf942.

39.

Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells.

Sutton P, Borgia JA, Bonomi P, Plate JM.

Mol Cancer. 2013 Jul 16;12:76. doi: 10.1186/1476-4598-12-76.

40.

A versatile fiber-optic fluorescence sensor based on molecularly imprinted microstructures polymerized in situ.

Ton XA, Tse Sum Bui B, Resmini M, Bonomi P, Dika I, Soppera O, Haupt K.

Angew Chem Int Ed Engl. 2013 Aug 5;52(32):8317-21. doi: 10.1002/anie.201301045. Epub 2013 Jun 21. No abstract available.

PMID:
23794218
41.

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.

Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI.

Clin Cancer Res. 2013 Jun 1;19(11):3068-77. doi: 10.1158/1078-0432.CCR-12-3381. Epub 2013 Apr 3.

42.

Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.

Bonomi PD, Mace J, Mandanas RA, Min M, Olsen M, Youssoufian H, Katz TL, Sheth G, Lee HJ.

J Thorac Oncol. 2013 Mar;8(3):338-45. doi: 10.1097/JTO.0b013e318282ded5.

43.

Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer.

Sher DJ, Gielda BT, Liptay MJ, Warren WH, Batus M, Fidler MJ, Garg S, Bonomi P.

Clin Lung Cancer. 2013 Jul;14(4):370-5. doi: 10.1016/j.cllc.2012.10.009. Epub 2012 Dec 20.

PMID:
23260389
44.

CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.

Bradly DP, Gattuso P, Pool M, Basu S, Liptay M, Bonomi P, Buckingham L.

Diagn Mol Pathol. 2012 Dec;21(4):207-13. doi: 10.1097/PDM.0b013e31825554b2.

PMID:
23111194
45.

Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.

Edelman MJ, Harb WA, Pal SE, Boccia RV, Kraut MJ, Bonomi P, Conley BA, Rogers JS, Messmann RA, Garon EB.

J Thorac Oncol. 2012 Oct;7(10):1618-21.

46.

Modulation of imprinting efficiency in nanogels with catalytic activity in the Kemp elimination.

Bonomi P, Servant A, Resmini M.

J Mol Recognit. 2012 Jun;25(6):352-60. doi: 10.1002/jmr.2180.

PMID:
22641533
47.

Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer.

Fidler MJ, Basu S, Buckingham L, Walters K, McCormack S, Batus M, Coon J 4th, Bonomi P.

Anticancer Res. 2012 May;32(5):1705-10.

PMID:
22593449
48.

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.

Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, Shapiro GI, Gandhi L.

Clin Cancer Res. 2012 Jun 1;18(11):3163-9. doi: 10.1158/1078-0432.CCR-11-3090. Epub 2012 Apr 11.

49.

Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls.

Fidler MJ, Shersher DD, Borgia JA, Bonomi P.

Ther Adv Med Oncol. 2012 Mar;4(2):51-60. doi: 10.1177/1758834011427576.

50.

PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy.

Fidler MJ, Morrison LE, Basu S, Buckingham L, Walters K, Batus M, Jacobson KK, Jewell SS, Coon J 4th, Bonomi PD.

Br J Cancer. 2011 Dec 6;105(12):1920-6. doi: 10.1038/bjc.2011.494. Epub 2011 Nov 17.

Supplemental Content

Loading ...
Support Center